Faeth Therapeutics (FTH) Capital Expenditures (2020 - 2026)

Faeth Therapeutics (FTH) has reported Capital Expenditures for 7 consecutive years, with $6000.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $6000.0; the trailing twelve-month figure through Jun 2026 stood at $6000.0 (down 62.5% YoY), and the FY2025 full-year result was $16000.0, down 89.04% from the prior year.
• Capital Expenditures retreated to $6000.0 in Q1 2026 per FTH's latest filing, from $16000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $250000.0 in Q3 2022 and bottomed at $6000.0 in Q1 2026.
• Historically, Capital Expenditures has averaged $74333.3 across 5 years, with a median of $37000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 96.1% in 2022, then soared 694.74% in 2023.
• Over 5 years, Capital Expenditures stood at $250000.0 in 2022, then tumbled by 88.4% to $29000.0 in 2023, then soared by 275.86% to $109000.0 in 2024, then plunged by 85.32% to $16000.0 in 2025, then plunged by 62.5% to $6000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $6000.0, $16000.0, and $109000.0 for Q1 2026, Q2 2025, and Q2 2024 respectively.